Alzamend Neuro
ALZN
13 hedge funds and large institutions have $447K invested in Alzamend Neuro in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
27% more capital invested
Capital invested by funds: $351K → $447K (+$95.8K)
18% more funds holding
Funds holding: 11 → 13 (+2)
1.76% more ownership
Funds ownership: 4.7% → 6.46% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$56.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$51K |
| 3 |
Morgan Stanley
New York
|
+$40.8K |
| 4 |
VF
Virtu Financial
New York
|
+$28.5K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$28.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$2 |
ALZN Hedge Fund Activity: Q4 2025 in Review
13 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q4 2025, worth a combined $447K — up 27% from $351K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ALZN positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, adding an estimated $56.9K. The largest seller was Citigroup, exiting entirely with an estimated $2 sold.
- 13 institutional investors held Alzamend Neuro (ALZN) as of Q4 2025, up from 11 in Q3 2025.
- Funds reported $447K of Alzamend Neuro stock for Q4 2025, up 27% quarter-over-quarter.
- 3 funds opened new Alzamend Neuro positions in Q4 2025 and 1 closed out, a net change of +2 holders.
- The largest Alzamend Neuro buyer in Q4 2025 was DRW Securities, an estimated $56.9K added.
- The largest Alzamend Neuro seller in Q4 2025 was Citigroup, an estimated $2 sold.
Based on aggregated 13F filings for Q4 2025.